Biovica® International

About Biovica®
Biovica develops and commercializes blood-based biomarker assays that improve the monitoring of modern cancer therapies and predict patient outcomes. The company’s DiviTum® TKa assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality.

Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. The DiviTum® TKa kit is 510(k) cleared,  CE-labeled, and MPA-registered.